EXO Biologics
About EXO Biologics
EXO Biologics develops biopharmaceuticals using extracellular vesicles (EVs) to create therapies for rare inflammatory diseases that do not respond to standard treatments. Their proprietary drug loading and delivery platform enhances the therapeutic potential of EVs, providing a safer and more consistent alternative to traditional cell-based therapies.
```xml <problem> Many rare inflammatory diseases do not respond to standard treatments, leaving patients with limited therapeutic options. Traditional cell-based therapies, while promising, can be inconsistent and pose safety risks. </problem> <solution> EXO Biologics develops biopharmaceutical therapies for rare inflammatory diseases by harnessing the potential of extracellular vesicles (EVs), also known as exosomes. Their approach focuses on maximizing the therapeutic potential of exosomes by loading them with specific therapeutic molecules and drugs, using a proprietary drug loading and delivery platform. This platform aims to provide a safer, more consistent, and potentially more cost-effective alternative to traditional cell-based therapeutic approaches. The company leverages a state-of-the-art GMP manufacturing platform to ensure high-quality EVs and exosomes from research to clinical use. </solution> <features> - Proprietary drug loading and delivery platform for enhanced EV therapeutic potential - Focus on rare inflammatory diseases with high unmet medical needs - GMP manufacturing platform for high-quality EV production - Development of therapeutic exosomes as a safer and more consistent alternative to cell-based therapies </features> <target_audience> The primary target audience includes patients suffering from rare inflammatory diseases that do not respond to standard treatments, as well as clinicians seeking safer and more effective therapeutic options. </target_audience> ```
What does EXO Biologics do?
EXO Biologics develops biopharmaceuticals using extracellular vesicles (EVs) to create therapies for rare inflammatory diseases that do not respond to standard treatments. Their proprietary drug loading and delivery platform enhances the therapeutic potential of EVs, providing a safer and more consistent alternative to traditional cell-based therapies.
Where is EXO Biologics located?
EXO Biologics is based in Liège, Belgium.
When was EXO Biologics founded?
EXO Biologics was founded in 2019.
How much funding has EXO Biologics raised?
EXO Biologics has raised 15290000.
- Location
- Liège, Belgium
- Founded
- 2019
- Funding
- 15290000
- Employees
- 23 employees
- Major Investors
- Meusinvest (Noshaq)